X4 Pharmaceuticals Inc
(NAS:XFOR)
$
0.393
0.0036 (0.92%)
Market Cap: 67.03 Mil
Enterprise Value: 10.25 Mil
PE Ratio: 0
PB Ratio: 1.11
GF Score: 30/100 X4 Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
Sep 26, 2023 / 08:55PM GMT
Release Date Price:
$1.06
(+0.95%)
Kristen Kluska
Cantor Fitzgerald - Analyst
Okay, good afternoon, everybody. For our next presentation, I'm joined by Dr. Paula Ragan, CEO and President, and Adam Mostafa, CFO at X4 Pharmaceuticals. Welcome to our conference.
Paula Ragan
X4 Pharmaceuticals, Inc. - CEO & President
Great to be here, thank you.
Questions & Answers
Kristen Kluska
Cantor Fitzgerald - Analyst
Awesome. So, X4 is striving to be one of the pipeline in a platform stories in biotech, looking to understand how one drug candidate could potentially be impactful across a number of diseases. So, to start, could you please walk us through the role of CXCR4 has in retaining neutrophils in the blood marrow? Why is this problematic in the diseases that you're focused on?
Paula Ragan
X4 Pharmaceuticals, Inc. - CEO & President
Yeah, so CXCR4 is tied to the immune system. If folks were watching the Pfizer presentation just earlier, we wouldn't have vaccine responses or responses to
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot